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Abstract
Desmoid-type fibromatosis, also known as aggressive fibromatosis or desmoid 
tumors, are very rare neoplasms, accounting for 0.03% of all newly diagnosed 
neoplasms and less than 3% of all soft tissue tumors (Escobar et al. 2012). 
Desmoid tumors occur in different anatomic locations in musculoaponeurotic 
tissues and may be painful, although they are seldom fatal. Approximately 10% 
of desmoid tumors are associated with an inherited condition called familial 
adenomatous polyposis (FAP) while the majority of desmoid tumor patients 
harbor a somatic mutation in the CTNNB1 gene. Indolent tumors are 
surveilled; however, progressing and symptomatic desmoid tumors are 
managed with surgery, radiotherapy, or systemic therapy. Different systemic 
approaches include non-steroidal anti-inflammatory agents, endocrine 
therapy, tyrosine kinase inhibitors, and chemotherapy. 
This thesis evaluated the outcome of oncological treatments at Helsinki 
University Hospital. We tried to seek novel molecular markers to identify 
different risk groups. We also aimed to illuminate the underlying 
pathobiological mechanisms in desmoid tumors.
The patients were treated at Helsinki University Hospital between 1987 and 
2010 in study I (49 radiotherapies) and until 2011 in studies III (n = 76) and 
IV (n = 83). The patterns of recurrences after radiotherapy were analyzed 
using image co-registration. Response Evaluation Criteria in Solid Tumors 
(RECIST) 1.1. were utilized for response evaluation in studies I and II; 
additionally, World Health Organization (WHO) criteria were used in study II. 
Study II examined the effect of cyclin-dependent kinase inhibitor ribociclib 
together with endocrine treatment in a patient with multifocal desmoid 
tumors and FAP. A tissue microarray was built of the formalin-fixed paraffin-
embedded desmoid tumor specimen. The slides were immunohistochemically 
stained with Ki67, cyclin D1, cyclin A, and estrogen receptor β antibodies. 
Digitally assisted evaluation of the slides was carried out using Pannoramic 
Viewer software (3DHistech, Budapest, Hungary). 
5Radiation dose was independently associated with time to progression in 
patients treated with surgery combined with radiotherapy or radiotherapy 
alone (hazard ratio 0.71, p = 0.02). Local control rate was 75% at five years. 
The majority of recurrences after radiotherapy occurred at the margin of 
radiotherapy target (82%, 9/11), two were in-target (18%, 2/11), but none was
out-of-target. Ribociclin, goserelin, and letrozole reduced symptoms and 
stabilized multiple desmoid tumors in a patient with treatment-resistant 
multiple desmoid tumors for ten months. High expression of cyclin A 
predicted poor outcome after surgery (hazard ratio 1.9, p = 0.02) whereas Ki67 
or cyclin D1 expression rate did not reach statistical significance. Estrogen 
receptor β expression level had a positive association with proliferation.
This thesis is a comprehensive investigation of a rare disease entity. The
results demonstrate that radiotherapy is an effective treatment in desmoid 
tumors. High cyclin A expression is a novel risk factor for recurrence after 
surgery. 
Finnish summary 
Desmoidit ovat erittäin harvinaisia kasvaimia, jotka käsittävät 0.03% kaikista 
kasvaimista ja alle 3% kaikista pehmytkudoskasvaimista. Desmoidit kasvavat 
eri ruumiinosissa lihaksissa ja kalvojänteissä. Ne voivat aiheuttaa kipua, mutta 
johtavat vain harvoin kuolemaan. Noin 10%:lla desmoidipotilaista on 
familiaalinen adenomatoottinen polypoosi (FAP), kun suurimmalla osalla 
potilaista on somaattinen CTNNB1 geenimutaatio. Rauhallisesti käyttäytyviä 
kasvaimia seurataan, mutta kasvavia ja oireisia desmoideja voidaan hoitaa 
leikkaamalla, sädehoidolla tai lääkehoidoilla. Käytettyihin lääkehoitoihin 
kuuluvat tulehduskipulääkkeet, hormonaalinen hoito, tyrosiinikinaasin 
estäjät ja solunsalpaajat. 
Tämän väitöskirjan tavoitteena oli arvioida onkologisten hoitojen tuloksia 
Helsingin yliopistollisessa keskussairaalassa. Pyrimme etsimään uusia 
biomerkkiaineita, joiden avulla voisimme erotella ennusteellisia ryhmiä. 
Lisäksi tarkoituksemme oli valaista desmoidien kehittymisen ja kasvun 
taustalla vaikuttavia patologisia ja biologisia tapahtumia.   
Potilaat hoidettiin Helsingin yliopistollisessa sairaalassa vuosien 1987 ja 2010 
välillä tutkimuksessa I (49 sädehoitoa) ja vuoteen 2011 saakka tutkimuksissa 
III (n = 76) ja IV (n = 83). Sädehoidon jälkeisiä uusiutumia analysoitiin 
yhdistämällä kuvantamistutkimuksia sädehoitosuunnitelmiin. RECIST 1.1. 
kriteeristöä käytettiin hoitovasteiden arvioimisessa tutkimuksissa I ja II, 
lisäksi käytimme WHO kriteeristöä tutkimuksessa II. Tutkimuksessa II 
selvitettiin solusyklin estäjä ribosiklibin vaikutusta yhdessä hormonaalisen 
hoidon kanssa potilaalla, jolla oli FAP:iin liittyen useita desmoideja. 
Kudossirukokoelma koottiin parafiiniin valetuista ja formaliinilla 
kiinnitetyistä desmoidikudosnäytteistä. Objektilasit värjättiin 
immunohistokemiallisesti Ki67-, sykliini D1-, sykliini A- ja estrogeenireseptori 
β -vasta-aineilla. Näytteet arvioitiin tietokoneavusteisesti käyttäen 
Pannoramic Viewer -ohjelmistoa (3DHistech, Budapest, Hungary).  
7Sädehoitoannos oli itsenäisesti yhteydessä etenemisaikaan leikkauksen ja 
sädehoidon jälkeen tai yksin sädehoidon jälkeen (vaarasuhde 0.71, p = 0.02). 
Paikalliskontrolli oli 75% viiden vuoden kohdalla. Sädehoidon jälkeen suurin 
osa uusiutumista ilmaantui hoitokohteen reunalle (82%, 9/11), kaksi oli 
sädehoitokohteessa (18%, 2/11), mutta yksikään ei kasvanut täysin 
kohdealueen ulkopuolella. Ribosiklibi, gosereliini ja letrotsoli vähensivät 
oireita ja vakauttivat monipesäkkeiset desmoidit kymmeneksi kuukaudeksi. 
Korkea sykliini A:n immunopositiivisuus ennusti nopeampaa uusiutumista 
leikkauksen jälkeen (vaarasuhde 1.9, p = 0.02), kun taas Ki67:n tai sykliini 
D1:n ilmentymisellä ei havaittu tilastollisesti merkittävää vaikutusta 
desmoidien uusiutumiseen. Estrogeenireseptori β:n korkeampi 
immunopositiivisuus oli yhteydessä solujen jakautumisnopeuteen.
Tämä väitöskirja sisältää perusteellisen selvityksen harvinaisesta 
kasvaintyypistä. Tuloksemme selvästi osoittavat, että sädehoito on 
desmoidien tehokas hoitomuoto. Korkea sykliini A:n immunopositiivisuus on 
uusi lisääntynyttä uusiutumisriskiä ennustava tekijä leikkauksen jälkeen. 
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1. Introduction
Desmoid tumors are mesenchymal neoplasms classified as intermediately 
malignant tumors (Fletcher, World Health Organization., and International 
Agency for Research on Cancer. 2013). Desmoid-type fibromatosis arises in 
deep soft tissues in muscles and fascial tissues in various anatomic sites,
including the extremities, trunk, and head and neck area. Higher incidence in 
fertile females indicates hormonal influence in desmoid tumor development 
and growth. Desmoid tumors occur sporadically or are inherited in the context 
of familial adenomatous polyposis (FAP). The main challenge is the local 
morbidity due to the occasionally aggressive behavior of these tumors and the 
high recurrence rate following surgery. The natural course of the disease varies
from indolent to life-threatening; however, desmoid tumors lack the 
propensity to metastasize.
The rarity of the disease and the variable biological behavior has led to 
difficulties in the formulation of treatment guidelines. Today treatment 
protocols recommend a first-line wait-and-see policy with close radiological 
monitoring (Kasper, Baumgarten, et al. 2017). Many of these patients require 
a change in the treatment strategy during the follow-up. Enlarging or 
symptomatic tumors should be managed, either operated or treated with 
radiotherapy or systemic therapy (Mehren et al. 2019). Clinical factors 
associated with worse outcomes after surgery include large tumor size and 
extremity location, young patient age, and positive resection marginals, 
although the results in different series have been inconsistent (Yao et al. 2014; 
Crago et al. 2013). Quality of life should be considered a top priority when 
selecting treatment modality. A multidisciplinary sarcoma team should be
responsible for the treatment design of this complex disease. The management 
of pediatric patients suffering from desmoid tumor has not been included in 
this study.
In this thesis, we investigated the efficacy of radiotherapy and explored the 
activity of a novel combination of ribociclib and endochrine therapies in taper 
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desmoid tumors. We also examined the underlying pathobiology and 
evaluated the expression and the predictive role of different proliferation 
biomarkers and estrogen receptor β (ERβ). A better understanding of desmoid 
tumor pathobiology could help in separating differing risk groups and finding 
novel therapies. 
2. Review of the literature
2.1. GENERAL
Desmoid tumors are uncommon fibroblastic neoplasms constituting less than
0.03% of all tumors. The word desmoid originates from the Greek word 
“desmos” describing the characteristic tendon- or band-like tissue of the 
tumor. In scientific literature abdominal wall desmoid tumor was first 
reported by MacFarlane in 1832 and subsequently named by Muller in 1838
(MacFarlane 1832; Muller 1838). The clinical behavior of these soft tissue 
tumors varies from spontaneous resolution to aggressive, infiltrative growth.
2.2. EPIDEMIOLOGY
Desmoid tumors’ estimated incidence is 2.4 to 4.3 per million inhabitants
annually in Finland (Reitamo et al. 1982). The incidence might be slightly 
underestimated due to underdiagnosis. A Dutch study, for example, observed 
a rising incidence from 2.1 to 5.4 per million people per year between 1993 and 
2013 (van Broekhoven, Grunhagen, et al. 2015). Desmoid tumors can occur in 
all age groups with a peak incidence from 30 to 40 years with female-male 
ratio of approximately 2:1 (Penel et al. 2016). The vast majority of desmoid
tumors occur sporadically, but at least 7.5% is associated with FAP 
(Nieuwenhuis, Casparie, et al. 2011). Between 10% and 20% of FAP syndrome 
patients develop desmoid tumor(s), and the risk is approximately 800-fold 
higher compared with the general population (Heiskanen and Jarvinen 1996; 
Nieuwenhuis, Lefevre, et al. 2011). Female predominance has not been 
observed in FAP carriers, and sporadic and FAP-related desmoid tumors are 
regarded as separate disease entities (Nieuwenhuis, Lefevre, et al. 2011).
2.3. PATHOPHYSIOLOGY
The vast majority of desmoid tumors show characteristic positive nuclear β-
catenin staining in immunohistochemistry. Activation of the Wnt/β-catenin 
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signaling pathway is caused by a mutation either in the β-catenin gene 
CTNNB1 or the tumor suppressor gene APC in up to 95% of sporadic desmoid 
tumor patients. In previous genomic studies, the occurrence of these 
mutations was lower, 85%; however, the next generation of sequencing 
techniques revealed nearly uniform alterations in the APC and CTNNB1 genes 
(Crago et al. 2015). Germline APC gene mutation causes FAP, a syndrome that 
is characterized by the development of hundreds of colon adenomas, and if left 
untreated, it can account for virtually 100% lifetime risk for the development 
of colorectal cancer. Gardner’s syndrome is a FAP subtype with typical 
manifestations of skull osteomas and skin and soft tissue tumors such as 
desmoid fibromatosis. The loss of the APC gene function disrupts the β-
catenin degradation complex formation, which subsequently causes the β-
catenin accumulation, as illustrated in Figure 1. Mutation in the CTNNB1 gene 
prevents β-catenin phosphorylation and further degradation in proteasome 
leading to β-catenin stabilization. In both APC and CTNNB1 mutations, the 
abundant cytoplasmic β-catenin translocates into the nucleus where it acts as 
a coregulator of TCF/LEF family of transcription regulators. They can further 
activate oncogenes.
Figure 1. In sporadic desmoid tumors mutation in the CNNB1 gene prevents phosphorylation
of β-catenin and therefore its proteosomal destruction. In patients with familial 
adenomatous polyposis, deficiency of the adenomatous polyposis coli (APC)
protein inhibits formation of β-catenin destruction complex. In both occasions 
accumulated cytoplasmic β-catenin translocates into the nucleus to activate target 
genes. Adapted from (Martinez Trufero et al. 2017).
2.4. CLINICAL FEATURES
The desmoid tumor is often presented as an asymptomatic soft tissue mass, 
which can cause pain or pressure when invading into adjacent tissues. 
Depending on the anatomic site, desmoid tumors can grow into nerves and 
vessels or cause compression and obstruction of ureters or small intestine. In 
the head and neck area, the desmoid tumor can induce dyspnoea. Tumor 
growth can lead to functional and cosmetic impairment, and in more 
complicated conditions, it can cause absence from work, retirement, or even 
death. After prophylactic colon surgery, desmoid tumors constitute a relevant 
risk for morbidity in FAP patients, given the frequent multifocal and intra-
abdominal presentation (Koskenvuo et al. 2016).
Desmoid tumors can appear virtually in all parts of the body. Sporadic tumors 
are more common in the trunk and limb girdles, whereas FAP-related tumors
often arise in the abdominal wall, mesenterially and multifocally (Figure 2. 
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Desmoid tumors lack the propensity to metastasize; however, it has been 
hypothesized that the circulation of mesenchymal progenitor cells could 
explain the multifocal appearance lesions in sporadic desmoid tumor patients 
(Bekers et al. 2018; Wu et al. 2010). This conception is based on an observation 
of the same gene mutation in different lesions per patient (Bekers et al. 2018).
Figure 2. Desmoid tumor localization in patients with the sporadic and FAP-associated 
disease (Nieuwenhuis, Lefevre, et al. 2011; Nieuwenhuis, Casparie, et al. 2011).
2.4.1. RISK FACTORS
Trauma, including surgery, is a risk factor for desmoid tumor development. 
FAP patients who have undergone prophylactic colorectal surgery have a 
higher risk for desmoid tumor presentation in the years following the 
abdominal operation (Nieuwenhuis, Lefevre, et al. 2011). The growth factors 
could explain the phenomenon in the initial phase of wound repair, which 
activates β-catenin mediated signaling. This development subsequently 
induces proliferation in wound fibroblasts (Cheon et al. 2004). Consequently, 
desmoid-type fibromatosis has been described as the uncontrolled growth of 
a scar. In FAP patients, prophylactic colon surgery may be postponed a few 
years to delay surgery-induced desmoid tumor development (ML et al. 2017). 
For FAP carriers, positive familial history and a mutation in the adenomatous 
polyposis coli (APC) gene 3’ codon increase the risk of desmoid tumors 
(Nieuwenhuis, Lefevre, et al. 2011). 
Another risk factor is pregnancy, during and shortly after which desmoid 
tumors typically emerge in the abdominal wall, particularly the rectus 
abdominis muscles. The elevated risk has been connected to hormonal 
influence and pregnancy-induced aponeural stretching. These tumors usually 
behave indolently and can, in many cases, be either observed or successfully 
resected. On the contrary, nearly half of women with existing sporadic
desmoid tumor experience disease progression during or after gestation. 
Therefore, careful monitoring during pregnancy is required. The complication 
risk depends on the tumor location, and for most patients, desmoid tumors 
can be treated successfully during pregnancy, although data of intra-
abdominal or retroperitoneal tumors are limited. Generally, pregnancy is not 
considered contraindicated in desmoid tumor patients (Fiore et al. 2014).
2.4.2. SCREENING FOR FAP
Desmoid fibromatosis may be the first manifestation of FAP, and colonoscopy 
should be considered for newly diagnosed desmoid tumor patients. In 
literature, endoscopic screening has revealed undiagnosed FAP in 1.3–3.7% of 
these patients (Koskenvuo et al. 2016; van Houdt et al. 2019). Diagnostic yield 
was higher in patients below 40 (11%), with intra-abdominal, retroperitoneal 
(5.4%), or multifocal tumors (29%), and in patients with a family history of 
FAP (8%). Tumoral CTNNB1 gene alteration seems to exclude APC mutation,
and therefore, patients harboring CTNNB1 tumor mutation may not require 
endoscopic screening (van Houdt et al. 2019). 
2.5. IMAGING
In the initial diagnostic phase in primary health care ultrasound can be 
feasible for patients presenting with a soft tissue mass. Subsequently, soft 
tissue lesion can be visualized with computed tomography (CT) or with 
magnetic resonance imaging (MRI) to evaluate the tumor diameter and 
adherence to adjacent structures. For intra-abdominal tumors, CT is the 
primary choice, whereas in other locations, due to the superior soft tissue 
contrast, MRI is the gold standard in desmoid tumor imaging. In non-contrast 
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CT often low attenuation of these tumors is close to attenuation of skeletal
muscles. Contrast enhancement varies from mild to medium and only 
infrequently desmoid tumors show prominent enhancement. Low MRI signal 
on T1-weighed images is a common feature for these tumors, whereas, in T2-
weighed images the signal intensity varies depending on lesion cellularity and 
collagen content (Figure 3) (Braschi-Amirfarzan et al. 2016). 18F-
fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has been 
investigated not only as a diagnostic imaging modality but also as an evaluative 
tool for the role of 18F-FDG uptake changes in the prediction of therapy 
response in desmoid tumors (Kasper et al. 2013). In clinical practice, 18F-FDG-
PET is seldom used in desmoid tumors.
Figure 3. Desmoid tumor growing in the upper back adjacent to the region previously 
operated because of osteoporosis. Concurrent unspecified findings in the lungs and 
thyroid gland proved to be a metastatic follicular thyroid carcinoma. The desmoid 
causing pain and discomfort was treated with 60 Gy in 2 Gy fractions radiotherapy. 
Six months after radiotherapy magnetic resonance imaging (MRI) displayed
decreased T2 signal intensity and stable disease.
2.6. HISTOPATHOLOGY
Extra-abdominal desmoid tumors arise from musculoaponeurotic or facial 
tissues, and intra-abdominal tumors stem from mesenteric folds or 
retroperitoneally. A percutaneous core needle biopsy, examined by an expert 
sarcoma pathologist, is useful to confirm the diagnosis. Macroscopically 
desmoid tumors are composed of pale tissue mass, strands, or plaques. Tumor
cells show fibroblastic or myofibroblastic differentiation. They consist of 
elongated spindle-like cells with often abundant collagen and vasculature with 
perivascular edema (Figure 4). Mitosis is generally rare, nuclear atypia is 
absent and cellularity is sparse (Fisher and Thway 2014; Fletcher, World 
Health Organization., and International Agency for Research on Cancer. 
2013).
Nuclear β-catenin expression is utilized in differential diagnostics as a 
diagnostic tool t0 distinguish these tumors from morphologically similar 
lesions and to confirm the diagnosis. The differential diagnosis includes other 
myofibroblastic lesions, perineurinomas, low-grade fibromyxoid sarcomas, 
gastrointestinal stromal tumors, and spindle cell liposarcomas (Fisher and 
Thway 2014). Between 82% and 100% of desmoid tumors show positive β-
catenin staining; however, a few other soft tissue lesions, such as solitary 
fibrous tumors and fibrosarcomas, also occasionally express β-catenin. 
Moreover, sample representativity, immunohistochemistry procedure 
(antibody clones, fixation, staining) and interpretation may affect the outcome 
in immunohistochemistry (Ng et al. 2005). Gene mutation analysis may be a 
more sensitive and specific method than immunohistochemistry in differential
diagnostics, although not as commonly available and associated with higher 
costs (Koike et al. 2019). In large series with up to 191 potential morphologic 
mimics, CTNNB1 mutation has not been detected in lesions potentially 
imitating desmoid tumors (Amary et al. 2007; Le Guellec et al. 2012). In 
patients treated with a non-surgical approach, the evaluation of β-catenin 
expression from a core needle biopsy may be challenging, and especially for 
these patients, CTNNB1 gene analysis may prove useful. In desmoid-type 
fibromatosis, the most frequently identified CTNNB1mutations are located in 
exon 3 codons 41 or 45, including three point mutations: T41A (substitutes 
threonine with alanine), S45F (substitutes serine with phenylalanine), and 
S45P (substitutes serine with proline) (Crago et al. 2015; Salas et al. 2010).
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Figure 4. (A) Desmoid tumors tumors often invade into adjacent tissues. (B) Tumors consist
of spindle-shaped cells with abundant vasculature. (C) Typical nuclear staining for
β-catenin by immunohistochemistry.
2.7. PREDICTORS OF POSTOPERATIVE RECURRENCE 
Desmoid tumors have the propensity to recur even after a complete resection 
with negative surgical margins. Local relapse most commonly occurs within 
two years following the initial treatment; however, recurrences after decades 
from primary treatment have been reported (Fiore et al. 2009). 
The significance of surgical margins has long been debated. Positive surgical 
margins predicted faster recurrence in many retrospective series (Nuyttens et 
al. 2000; Ballo et al. 1999; Merchant et al. 1999) but not in others (Lev et al. 
2007; Salas et al. 2011; Merchant et al. 1999). In a meta-analysis of 1295 
patients with a resected extra-abdominal desmoid tumor, the positive surgical 
margin increased the risk for recurrence almost twofold (hazard ratio [HR] 
1.78, 95% confidence interval [CI] = 1.4–2.26) (Janssen et al. 2017). Besides 
marginals, young age under 25 and upto to 37 years, tumors size over 4–10 
centimeters, and limb location have independently predicted local recurrence 
following surgery (Yao et al. 2014; Crago et al. 2013; Salas et al. 2011). To aid 
decision-making, a nomogram to predict postsurgical relapse was created and 
validated using age, tumor localization, and size as variables (Crago et al. 
2013). Moreover, in sporadic desmoid tumors, a specific CTNNB1 mutation 
S45F predicted elevated risk for recurrence after surgery (Colombo et al. 2013; 
Lazar et al. 2008; van Broekhoven, Verhoef, et al. 2015; Domont et al. 2010). 
However, not all reports confirmed these results (Romero et al. 2012; Mullen 
et al. 2013). A meta-analysis combining all these studies might clarify the role 
of S45F mutations in desmoid tumor biology.
2.8. MANAGEMENT
During recent years, the management of desmoid tumors has changed from 
initial radical surgery into a more conservative approach. The National 
Comprehensive Cancer Network guidelines suggest therapy including surgery, 
systemic therapy, or radiotherapy for progressive or symptomatic desmoid
(Mehren et al. 2019). Individualized therapy design in multi-professional 
collaboration is recommended. Patient preference should be taken into 
account after being informed about the risks and benefits of different 
treatment policies.
2.8.1. SURVEILLANCE
The European Consensus Initiative advocates an initial follow-up period 
before further management of desmoid tumor patients (Kasper, Baumgarten, 
et al., 2017). The watchful waiting policy originates from observations that 
even without any treatment, desmoid tumors may undergo unpredictable 
phases of tumor growth, stabilization, and spontaneous regression (20–30% 
of tumors) (Colombo et al. 2015). In retrospective surveillance studies, the 
local control rate has varied from 60% to 92%, with the highest rate of 
prolonged stabilization in abdominal wall tumors (Briand et al. 2014; Barbier 
et al. 2010; Fiore et al. 2009; Huang et al. 2014; Salas et al. 2011). The 
advantage of follow-up strategy is that a portion of patients avoids the 
morbidity related to surgery, radiotherapy, or medical therapy. The 
observational strategy requires frequent imaging to detect rapid growth or 
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impending infiltration or compression to adjacent vulnerable structures 
(Braschi-Amirfarzan et al. 2016). During follow-up, clinical control and 
imaging may be performed every 3 to 6 months for the first 2 to 3 years and 
after that every six months or annually (Mehren et al. 2019). The optimal 
length of surveillance continues to be an open question.
The factors responsible for progression at surveillance of desmoid tumors have 
remained unknown. Predictive factors for unfavorable outcome in surgically 
treated patients cannot be applied to patients who are observed. A few studies 
have examined whether changes in MRI signal intensity predict progression 
during follow-up with contradictory results (Castellazzi et al. 2009; Healy et 
al. 1997). In a recent series of 37 observed patients, hyperintense T2 signal in 
≥ 90% of tumor volume predicted progression (Cassidy et al. 2018). Currently,
the wait-and-see strategy is explored in several prospective trials 
(NCT01801176, NCT02547831, and NTR4714) (van Broekhoven et al. 2016).
2.8.2. SURGERY
A decade ago, the mainstay of the treatment was surgery. The accumulating 
evidence of observational policy led to a change of management guidelines.
Upfront surgical therapy may be necessary if desmoid tumor impairs function 
or in case of emergencies, such as intestinal obstruction or perforation. The 
goal of surgical resection is to obtain clear margins (R0) (Table 1), preserving
function and esthetic appearance. In some occasions, reconstructive surgery 
may be needed. Considering the infiltrative growth pattern, obtaining negative 
margins may be a challenge, especially in specific locations such as the limb
girdles, head and neck area, and the small bowel mesenterium. Negative 
margins should not be attempted sacrificing neurovascular or other critical 
structures, given that not all tumors recur even after margin positive surgery. 
For extra-abdominal desmoid tumors, the local control rate of after surgery 
has varied from 47% to 86% whereas the outcome following abdominal wall 
tumor resection seems superior with a recurrence rate of only 5% (Wilkinson 
et al. 2014; Smith et al. 2018). An abdominal mesh can be used to repair the 
defect in the resection site. 
Table 1. Classification of surgical margins. (Adapted from The eighth edition AJCC Cancer 
Staging manual: Continuing to build a bridge from a population-based to a more “personalized” 
approach to cancer staging) (Amin et al. 2017)
R0 No residual tumor Negative/free/clear margins
R1 Microscopic residual tumor Intralesional resection/ 
positive marginsR2 Macroscopic residual tumor
The vast majority of tumors in the abdominal cavity grow in the root of 
mesenteric vessels. Depending on the tumor site and size, resection of an intra-
abdominal desmoid tumor may lead to small bowel resection and cause 
significant morbidity (Latchford et al. 2006). A stable and symptomless intra-
abdominal tumor can be followed; however, in other cases, surgical 
resectability should be assessed, and potential benefits and disadvantages 
should be weighed against those of systemic therapy.
2.8.3. RADIOTHERAPY
In the adjuvant setting, radiation has been used after margin-positive 
resection. However, similar to resection marginals, adjuvant radiotherapy has 
been a controversial issue in desmoid tumor management (Crago et al. 2013; 
Yao et al. 2014). In a meta-analysis, adjuvant radiotherapy following resection 
with R1 or R2 margins reduced the risk for relapse; however, the effect was
more prominent in the group with recurrent desmoid tumors. Radiotherapy 
after surgery with R0 margins was not associated with improved prognosis 
(Janssen et al. 2017). Taking into account long-term radiation-related toxicity 
and given that only about one third of the primary tumors after a resection 
with R1 margins recur, postoperative radiotherapy is recommended in 
recurrent desmoid tumors after intralesional resection if re-resection of a 
relapse would be potentially harmful (Janssen et al. 2017; Kasper, 
Baumgarten, et al. 2017). 
Surgery combined with adjuvant radiotherapy and radiotherapy as the sole 
treatment have demonstrated similar local control rates (Guadagnolo, Zagars, 
27
and Ballo 2008; Keus et al. 2013). Therefore, if inadequate surgical margins 
appear likely after an upfront operation, radiotherapy alone can be delivered 
to avoid surgery-related morbidity. For intra-abdominal desmoid 
fibromatosis, radiation is seldom used due to the proximity of radiosensitive 
organs and a high risk of radiation-induced enteritis.
2.8.3.1. Treatment planning and dose
The goal of radiotherapy is to target the tumor volume or the operative bed 
with an adequate dose sparing the adjacent healthy tissues. Treatment 
planning simulation is performed with either CT or MRI patient fixed in the 
treatment position. The clinical target volume (CTV) includes the microscopic 
disease surrounding the gross tumor volume (GTV). Usually, 5-cm margins
have been utilized vertically, and 2-cm ones have been used in other directions, 
excluding the natural barriers, such as bones and fascial planes (Keus et al. 
2013; Guadagnolo, Zagars, and Ballo 2008). The infiltrative growth pattern
emphasizes the significance of wide margins in desmoid tumors (Zlotecki et 
al. 2002). Given the tumor location, both the photon beam and electrons can 
be implemented using individually appropriate techniques.
A favorable dose-response has been described (Choi et al. 2018; Spear et al. 
1998). Radiotherapy alone for inoperable progressing desmoid tumors using 
moderate dose radiation with fractionation scheme of 56 Gy in 28 fractions 
yielded a local control rate of 82% at three years in a prospective multicenter 
phase II study (Keus et al. 2013). Higher doses from 60 to 65 Gy have been 
employed; however, doses higher than 56 Gy were associated with a higher 
rate of radiation-induced complications (Guadagnolo, Zagars, and Ballo 
2008). In the case of microscopic residual tumor, 50 Gy is considered a 
sufficient dose, whereas, for tumors with a macroscopic residual or gross 
tumor, 50–56 Gy is recommended. Radiation therapy can be delivered in two 
phases using the shrinking field technique, first attending to 50 Gy and then 
boosting the gross tumor volume. 
2.8.3.2. Radiation-related toxicity
In the treatment of a semi-malignant tumor, the risk for secondary cancer and 
long-term sequelae should be marked, especially in the young patient group.
Toxicity depends on the irradiated site, volume, dose, and individual 
sensitivity for radiation. Acute radiation-related toxicity, such as skin 
irritation, is often reversible, whereas late toxic effects can be long-lasting. 
Late toxic effects include joint and muscle stiffness, lymphedema, fibrosis, 
skin effects, neuropathy, bone fracture, and osteonecrosis, for example. 
Second malignancy in the irradiated volume is a rare event. (Guadagnolo, 
Zagars, and Ballo 2008; Yao et al. 2014) Continuously improving imaging and 
radiation techniques reduce the irradiation of healthy tissues.
2.8.4. OTHER LOCOREGIONAL THERAPIES
Percutaneous cryoablation and radiofrequency ablation are minimally 
invasive local treatment investigated in desmoid tumors (Ilaslan et al. 2010; 
Schmitz et al. 2016). Percutaneous cryoablation and radiofrequency ablation 
allow the management of lesions with diameters approximately up to 10 cm or 
5 cm, respectively, or larger tumors within multiple treatment times. 
Involvement or proximity of critical tissues limits the use of both treatment 
modalities. Ultrasound-guided or magnetic resonance-guided high-intensity 
focused ultrasound is a non-invasive treatment suitable also for larger
desmoid tumors (Ghanouni et al. 2017; Zhao et al. 2016). If tumor eradication 
is sought, the tumor should be separated from skin and nerves. In a desmoid 
tumor series, the most common reported adverse effect was skin burn, and the 
most challenging complication was nerve injury (Ghanouni et al. 2017). The 
advantages of these locoregional treatments include repeatability and safety. 
The initial results in small retrospective series have been promising, although
more extensive prospective trials and longer follow-up time are warranted.
Isolated limb perfusion with tumor necrosis factor α and melphalan showed 
clinical benefit in locally advanced extremity desmoid tumors where surgery 
would have resulted in mutilation (van Broekhoven et al. 2014). The response 
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rate (RR) was 68% (19/28), and after seven years of median follow-up time, 
disease progression was observed following 39% (11/28) of initial treatment 
with isolated limb perfusion. Toxicity was mostly modest, including erythema 
and edema, although there is a risk for more severe complications. The role of 
these locoregional techniques in treatment algorithms is unclear, although, in 
specialized centers, they offer an additional alternative. 
2.8.5. SYSTEMIC THERAPY 
Desmoid tumors are uncommon, and their behavior is unpredictable, 
including periods of growth and regression, which makes the evaluation of 
medical therapies demanding. Various therapeutic agents have been used in 
desmoid tumor management; however, these therapies have rarely been 
compared with each other in clinical trials. There is no consensus about the 
sequence of medical agents. Despite being challenging, it has highly been 
encouraged to enroll desmoid tumor patients in prospective and randomized 
clinical trials. This approach is needed to provide high-level evidence-based 
treatment guidelines in the future.  
Table 2. Response evaluation criteria in solid tumors (e.g., RECIST 1.1. guidelines) (Adapted from 
Eisenhauer et al. New response criteria in solid tumours: revised RECIST guideline (version 1.1.) 
Eur J Cancer 2009) (Eisenhauer et al. 2009) 
Complete response (CR) Disappearance of all target lesions
Partial response (PR) At least a 30% decrease in the sum of 
diameters of target lesions, taken as 
reference for the baseline sum diameters 
Progressive disease (PD) At least a 20% increase in the sum of 
diameters of target lesions, taken as 
reference for the smallest sum on study 
Stable disease (SD) Neither sufficient shrinkage to qualify for 
PR nor sufficient increase to qualify for 
PD, taken as reference for the smallest 
sum diameters while on study 
2.8.5.1. Non-steroidal anti-inflammary drugs 
The complete shrinkage of an inoperable thoracic desmoid tumor during the 
treatment with indomethacin for pericarditis led to the use of NSAIDs in 
desmoid tumors (Waddell and Gerner 1980). Pericarditis was induced by 
preceding radiotherapy, and when assessed afterward, a late response for 
radiotherapy may have contributed to the tumor response. After that, NSAIDs 
were utilized in the management of desmoid tumors. NSAIDs, such as 
meloxicam, sulindac, or celecoxib, can be administered as first-line therapy 
due to their minimal toxicity. Additionally, NSAIDs prevent the development 
of premalignant colonic polyps in patients with FAP. 
NSAIDs inhibit cyclooxygenase (COX) 1 and 2 enzymes. In desmoid tumors, 
the upregulation of COX 2 may be due to stabilized β-catenin acting as a 
coactivator for T-cell factor/lymphoid enhancer factor (tcf-lef) family of 
transcription factors. These transcription factors promote genes that regulate 
proliferation, differentiation, and apoptosis, including COX 2 (Signoroni et al. 
2007). In desmoid tumors, the immunohistochemical expression of COX 2 has 
varied from 50% to 100% (Cho et al. 2018; Nishida et al. 2010; Signoroni et al. 
2007). Furthermore, COX 2 inhibition in desmoid tumor cell cultures resulted 
in reduced proliferation, and in vivo mouse models COX 2 inhibition reduced 
desmoid tumor sizes (Poon et al. 2001). 
The activity of NSAIDs has been documented in successful case reports, and 
the RRs in minor series have varied from 25% to 57% (Cho et al. 2018; Janinis 
et al. 2003; Nishida et al. 2010; Tanaka et al. 2008). In combination with 
endocrine therapy, NSAIDs have yielded similar RRs as in monotherapy with 
these agents (Quast et al. 2016). A retrospective study of 20 patients with an 
extra-abdominal desmoid tumor found no correlation between the outcome of 
meloxicam and the expression of COX 2 in tumor cells (Cho et al. 2018). 
Moreover, the results were compared with active surveillance studies in extra-
abdominal desmoid tumors. Thirteen of 20 patients (65.0%) in the meloxicam 
study reached SD or PR, whereas, in the surveillance studies, 80.3% (167/208) 
of desmoid tumor patients experienced either tumor growth arrest or 
regression (Cho et al. 2018). Today the position of NSAIDs in desmoid tumor 
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therapy is restricted to patients with slowly growing desmoid tumors and mild 
symptoms. 
2.8.5.2. Hormonal therapy 
Endocrine treatment is often a well-tolerated and affordable option for 
frontline therapy in desmoid tumors. Selective estrogen receptor modulators 
(SERM) such as tamoxifen, toremifene, and more uncommonly raloxifene 
have been used for desmoid tumors in doses parallel to breast cancer and 
tamoxifen, as high-dose therapy can reach up to 160 mg daily (Brooks et al. 
1992; Fiore et al. 2015). The efficacy of hormonal therapy has been varied, and 
it is based on case reports and uncontrolled series. A systematic review 
summarized endocrine treatments with a RR of 51% with a 9-month median 
duration of treatment, whereas, in a prospective phase II study on children, 
the RR remained at 8% and progression-free survival (PFS) was 36% at two 
years (Bocale et al. 2011; Skapek et al. 2013). Only anecdotal cases of treatment 
with aromatase inhibitors and gonadotropin-releasing hormone (GnRH) 
analog have been reported (Bauernhofer et al. 1996; Debled et al. 2012; 
Wilcken and Tattersall 1991). 
2.8.5.3. Chemotherapy 
Chemotherapy is usually used for inoperable desmoid tumors in case of rapid 
growth. Both low dose agents and traditional dose chemotherapy have been 
administered, including anthracyclines and methotrexate in combination with 
vinca-alkaloids. A retrospective Italian study of methotrexate plus vinca-
alkaloid yielded a RR of 48% and a median PFS of 75 months with 75 patients 
(Palassini et al. 2017). In a retrospective study, the French Sarcoma Group 
reported a higher 54% RR with anthracycline-based chemotherapy (n = 13) 
compared with a 12% RR with non-anthracycline regimens (e.g., the 
combination of methotrexate and vinblastine) (n = 27). The median PFS of 41 
months did not differ significantly between the groups (Garbay et al. 2012). 
Adverse events such as severe myelotoxicity, anthracycline-induced 
cardiotoxicity, and elevated risk of secondary leukemia limit the use of 
chemotherapy. Liposomal doxorubicin is often recommended to avoid cardiac 
toxicity. 
2.8.5.4. Tyrosine kinase inhibitors 
Tyrosine kinase signaling pathways regulate cell growth and proliferation. 
Imatinib was the first tyrosine kinase inhibitor with described activity in 
desmoid tumors (Mace et al. 2002). Imatinib inhibits a limited number of 
tyrosine kinases, such as platelet-derived growth factor receptor (PDGFR)-α, 
PDGFR-β, stem cell receptor c-KIT, and nonreceptor tyrosine kinase ABL. In 
prospective trials of imatinib with 141 patients overall, the RR has varied from 
6% to 18%, and 1-year PFS has varied from 37% to 66% with tolerable side 
effects (Chugh et al. 2010; Heinrich et al. 2006; Kasper, Gruenwald, et al. 
2017; Penel et al. 2011). No significant correlation between the response and 
c-KIT, PDGFR-β, or other candidate target proteins were detected (Chugh et 
al. 2010). With sunitinib, a higher RR of 26% and a 2-year PFS of 74% was 
documented in a prospective phase II study with 19 patients (Jo et al. 2014). 
Pazopanib is another multitarget tyrosine kinase inhibitor investigated in 
small series of desmoid tumor patients (Agresta et al. 2018; Martin-Liberal et 
al. 2013; Szucs et al. 2017). Moreover, a non-comparative randomized phase 
II trial evaluated the activity of pazopanib (n=46) or methotrexate combined 
with vinblastine (n=20) in progressive desmoid tumors. Treatment with 
pazopanib demonstrated a RR of 37% and a 2-year PFS of 67% whereas in the 
chemotherapy group the RR was 25% and 2-year PFS was 79%. (Toulmonde 
et al. 2019) Compared with imatinib, sunitinib and pazopanib target a broader 
spectrum of tyrosine kinases, including PDGFR, c-KIT, vascular endothelial 
growth factor receptor (VEGFR), and receptor tyrosine kinase RET with 
differing affinity to the receptors. VEGFR overexpression has been linked with 
aggressive growth in desmoid tumors (Matono et al. 2011) 
Sorafenib is a multikinase inhibitor, which besides targeting PDGFR, VEGFR, 
and RET, also inhibits RAF- and MAP-kinase pathways. A retrospective study 
of sorafenib with 62 evaluable patients obtained a similar RR of 18% with a 
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differing affinity to the receptors. VEGFR overexpression has been linked with 
aggressive growth in desmoid tumors (Matono et al. 2011)
Sorafenib is a multikinase inhibitor, which besides targeting PDGFR, VEGFR, 
and RET, also inhibits RAF- and MAP-kinase pathways. A retrospective study 
of sorafenib with 62 evaluable patients obtained a similar RR of 18% with a 
median PFS of 48 months (Munhoz et al. 2016). In a recent randomized 
prospective phase III trial with 87 patients, the RR was 33%, and the 2-year 
PFS was 81% in the sorafenib group compared with RR of 20% and 2-year PFS 
of 36% in the placebo group (HR 0.13) (Gounder et al. 2018). The start dose 
for sorafenib was 400 mg once daily, which is lower than in other indications. 
The results of the biomarker study based on 25 sets of paired biopsy specimen 
are awaited.
The challenge with a rare disease entity is generally the unavailability of 
financial reimbursements for systemic agents. This concerns not only tyrosine 
kinase inhibitors but also other outpatient medical therapies. At present, no 
medicines are accepted for reimbursement for desmoid tumor patients in 
Finland.
2.8.5.5. Other therapies
The activity of interferon alpha is based on single case reports (Fernberg et al. 
1999; Stengel et al. 2008). Adverse effects of especially the non-pegylated 
formulation are common and often severer, including asthenia, flu-like 
symptoms, hematologic toxicity, and depressive symptoms. Pegylated 
interferon with a more favorable side-effect profile is not available in Finland. 
Besides, the subcutaneous administration, at least three times per week, may 
limit the use of interferon alpha. The biological basis for the use of interferon 
in desmoid tumors is unclear. 
In a phase I dose-escalation study, a novel therapeutic agent, oral γ-secretase 
inhibitor PF-03084014, demonstrated a promising activity with RR of 71% 
(5/7) in desmoid tumors (Messersmith et al. 2015). γ-Secretase activates 
Notch signaling, which is commonly deregulated in cancer and interacts with
the Wnt/β-catenin pathway (Rodilla et al. 2009). The long-term follow-up 
study showed no disease progression in five patients who achieved PR at 
follow-up from 48 to 73+ months (Villalobos et al. 2018). In a phase II study 
with 17 patients, γ-secretase inhibitor PF-03084014 achieved a PR rate of 
29%. Furthermore, during the median follow-up time of 25 months, eleven 
patients had SD (Kummar et al. 2017). With a dose of 150 mg twice per day,
the most common grade 1/2 adverse effects were diarrhea and skin toxicity. 
The only grade 3 side effect was reversible hypophosphatemia (Kummar et al. 
2017). A randomized placebo-controlled phase III study is underway
(NCT03785964).
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2.9. CYCLINS AND CYCLIN-DEPENDENT KINASES IN 
CELL CYCLE REGULATION
Disturbances in the cell division are a hallmark of cancer-driving cells, which 
leads into malignant proliferation. Cyclins and cyclin-dependent kinases (cdk)
are critical players in the strictly regulated cell cycle. Peaking of specific cyclins
activate cdks, which are present throughout the cell cycle. As a complex, they
promote cell cycle progression via phosphorylation, whereas cdks are
negatively regulated by naturally occurring cyclin-dependent kinase inhibitory
proteins, such as the INK4, CIP, and KIP families (Sherr and Roberts 1999).
Cells enter the cell cycle from the quiescent phase G0 or straight after the 
previous cell division. In the first gap phase, G1 retinoblastoma tumor 
suppressor protein (Rb) serves as a regulatory restriction point (Figure 5). 
Before the restriction point, mitogenic signaling, such as RAS, estrogen, and 
Wnt-β-catenin, promotes cell cycle progression by inducing an increase in 
cyclin D expression level. D-type cyclins bind to cdk 4, which then
phosphorylate and partly inactivate Rb. After that, Rb unbinds E2F family of 
transcription factors, which promotes cyclin E, A, and cdk2 and other factors 
associated with mitosis. In the late G1 phase, cyclin E and cdk2 complex
completely deactivates Rb by hyperphosphorylation and driving the transition
from G1 checkpoint to DNA synthesis (S) phase. After passing the restriction 
point, cell division proceeds independently of external growth signals. 
Following DNA replication in S phase, cyclin A peaks and pairs with cdk 2,
leading to the second gap phase (G2). The cell continues growing and prepares 
itself for mitosis in the G2 phase where it exits once cyclin B and its partner
cdk 1 are activated in the second checkpoint. In the mitotic phase (M), the 
nucleus is divided, followed by cytokinesis. After cyclin B-cdk1 complex 
degradation, the cell exits the M phase to form two daughter cells. In addition
to the canonical functions, cyclins and cdks have cell-cycle-independent roles,
such as the modulation of transcriptional activity via activation of RNA 
polymerase II (Diaz-Moralli et al. 2013). 
If a phase is not properly completed, cell division is stopped in order to prevent 
the development of defected and unviable cells. If repairment is not achieved,
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this can lead to either apoptosis or shifting the cell into the resting phase G0
(Diaz-Moralli et al. 2013).
Figure 5. In the first gap phase (G1) of the cell cycle cyclin-dependent kinases (cdk) 4 and 6 
bind with D-type cyclins and phosphorylate retinoblastoma susceptibility protein Rb
which inhibits E2F family of transcription factors. Growth factors, such as sex 
hormones, increase the expression of cyclin D. Rb is further phosphorylated by 
cdk2-cyclin E complex leading to increased transcription of factors involved in
mitosis and finally to cell cycle progression into phase S. Modified from (Ribnikar, 
Volovat, and Cardoso 2019)
In neoplasms, cell division can be dysregulated in many ways. P16INK4A-cyclin 
D-cdk4/6-Rb pathway aberrations frequently occur in various cancer types,
including the inactivation of inhibitory proteins INK4 and CIP/KIP and the 
overexpression or amplification of CDK4/6, CCND1, and Rb mutations. D-
type cyclins include cyclin D1, D2, and D3, of which cyclin D1 expression is the
most frequently altered and also the most widely investigated (Qie and Diehl 
2016; Ingham and Schwartz 2017). Cyclin D1 overexpression has been 
associated with poor prognosis in several cancer types, such as breast and 
prostate (Aaltonen et al. 2009; Fleischmann et al. 2011; Xu et al. 2013). Data
on the clinical significance of cyclin A protein expression in cancer is
comparatively limited. In renal cell carcinoma, endometrial carcinoma, and
soft tissue sarcoma, high cyclin A expression has shown an unfavorable effect 
on the outcome (Aaltomaa et al. 1999; Huuhtanen et al. 1999; Santala et al. 
2014).
2.9.1. CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS
The first-generation of non-specific cdk-inhibitors exhibited a high rate of 
adverse effects, which limited the dose and efficacy. Finally, the invention of 
cdk-specific inhibitors reduced toxicity and led to successful clinical trials. The 
first-in-class oral inhibitor of cdk4 and 6 was palbociclib, which, when 
combined with endocrine therapy, was perceived as a breakthrough in the 
management of advanced estrogen-receptor-positive human epidermal 
growth factor receptor 2 (HER2) -negative breast cancer (Cristofanilli et al. 
2016). Currently, two other cdk4/6 inhibitors—ribociclib and abemaciclib—
are approved by the US Food and Drug Administration and European 
Medicines Agency with the indication for advanced hormone receptor-positive 
breast cancer (O'Shaughnessy et al. 2018; Goetz et al. 2017). The improved
progression-free survival and RRs are comparable to all three cdk4/6 
inhibitors, whereas slight differences in adverse effects exist. Cdk 4/6 
inhibitors arrest the cell cycle in the mid G1 phase, although they do not have
a cytotoxic effect (Figure 5). The most frequent dose-limiting adverse event of 
all these drugs is myelotoxicity; however, neutropenic infections are rare.
Today all these agents are investigated in numerous clinical trials as a 
monotherapy and combined with other medication or radiotherapy in 
different malignancies. Cdk 4/6 inhibitors have demonstrated efficacy for 
example in melanoma, non-small cell lung carcinoma, head and neck
squamous cell carcinoma, ovarian cancer and liposarcoma (Schettini et al. 
2018; Adkins et al. 2019). In a phase II trial of advanced well-
differentiated/dedifferentiated liposarcoma treatment with single-agent 
palbociclib showed a favorable 12-week PFS rate of 57% when compared with 
an expected 12-week PFS of 40% for an active second-line medical agent in 
historical series. The majority of these tumors (>90%) display CDK4
amplification and they commonly express Rb. (Dickson et al. 2013; Dickson et 
al. 2016)
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2.10.ESTROGEN RECEPTORS AND CANCER
Estrogen receptors belong to the superfamily of nuclear receptors, which 
regulate gene expression in target tissues both in physiological and
pathological processes. The two main isoforms are estrogen receptor α (ERα) 
and ERβ. The DNA-binding domains differ only slightly as they have 96% in
common, whereas in the ligand-binding domain there is only 60% homology. 
In addition to natural estrogen receptor ligand 17β-estradiol, SERM, such as 
tamoxifen, can serve as ligands for both receptor types with tissue-specific 
agonist/antagonist action (Kuiper et al. 1997). Once the ligand binds to the 
receptor, ERα and ERβ dimerize either as homodimers (αα or ββ) or 
heterodimers (αβ) (Cowley et al. 1997). The conformational changes of the 
dimers enable their binding with estrogen-responsive elements of DNA 
promoters in the target genes followed by interaction with co-regulators. In 
addition to the classical genomic pathway, the effects of estrogens are 
conveyed by the non-genomic pathway. Estrogen signaling triggers protein-
kinase cascades via the third estrogen receptor, G-protein coupled estrogen 
reseptor 1, and it is connected with epigenetic regulation mechanisms (DNA 
methylation, micro RNA:s, histone modifications) both upstream and 
downstream (Filardo et al. 2007; Vrtacnik et al. 2014).
ERα expression predicts beneficial response for hormonal therapy in breast 
cancer, and in hormonally treated patients, it predicts favorable prognosis.
ERβ has shown anti-proliferative properties, and it has been associated with 
both increased disease-free survival and overall survival in breast carcinoma 
(Tan et al. 2016; Honma et al. 2008; Nakopoulou et al. 2004). It has been 
proposed that ERα and ERβ heterodimers decrease binding of coregulators 
and thus the transcriptional activity of ERα (Haldosen, Zhao, and Dahlman-
Wright 2014). However, the studies of ERβ impact on breast cancer outcome 
have reported inconsistent results, which may be because of several ERβ 
receptor subtypes and differences in ERβ function, depending on the presence 
of ERα and disease stage. In other cancer types, the function of estrogen 
receptors is less investigated. In colorectal and prostate carcinoma, ERβ acts 
as a tumor suppressor (Niv 2015; Weihua et al. 2002). On the contrary, in 
pancreatic carcinoma, ERβ expression correlates with adverse prognosis, and 
in bladder cancer, ERβ promotes growth and metastasis (Ou et al. 2018; 
Seeliger et al. 2018).
Endometrial carcinomas are estrogen-dependent tumors. In contrast to breast 
cancer, signaling via progesterone receptor (PgR) opposes the actions of 
estrogen and inhibits proliferation in the uterus and ovaries. The most 
common gynecological sarcomas, uterine leiomyosarcoma and endometrial 
stromal sarcoma, both express ERα and PgR, whereas little is known about 
significance of ERβ. Endometrial stromal sarcoma is an often indolent 
hormone-sensitive malignancy, managed at early-stage operatively and with 
adjuvant progestin and in metastatic phase with progestins, aromatase 
inhibitors or gonadotropin-releasing analogs (Amant et al. 2014).  The 
predictive role of steroid receptor expression, however, has not been 
confirmed in small-scale studies of this rare entity. In endometrial stromal 
sarcoma ERα, as well as PgR and androgen receptor positivity, have all been 
connected with improved survival (Park et al. 2018). Uterine leiomyosarcoma 
is a more aggressive mesenchymal tumor treated primarily with surgery and 
in metastatic stage with chemotherapy and targeted drugs. Case reports and 
small series have implied activity for endocrine therapy. Moreover, in a phase 
II study aromatase inhibitors demonstrated beneficial outcome for uterine 
leiomyosarcoma patients with high levels of ERα and PR expression (George 
et al. 2014). Similarly with endometrial stromal sarcoma, in leiomyosarcoma 
high ERα and PR expression have shown to be prognostic for favorable 
outcome (Akhan et al. 2005; Raspollini et al. 2003).
In extrauterine soft tissue sarcomas the role of estrogen signaling is more 
uncertain, although ERα and ERβ are expressed in different types of healthy 
mesenchymal tissues including for example vascular smooth muscle, adipose 
tissue and peripheral nerves. In ERα negative and ERβ positive
rhabdomyosarcoma cell lines estrogen stimulated proliferation indicating 
ERβ-mediated signal transduction (Greenberg et al. 2008). In contrast in a 
series of variable soft tissue sarcomas either ERα or ERβ immunoexpression 
correlated with proliferation (Li, Hisaoka, and Hashimoto 2003). 
41
Furthermore, the prognostic significance of hormone receptors in unclear. In 
a soft tissue sarcoma study ERα negativity and PgR positivity were together
prognostic for poor survival whereas a large liposarcoma study failed to show 
a connection between PgR expression and disease-free survival (Valkov et al. 
2011; Ingram et al. 2014). With over 50 subtypes, the expression of estrogen 
receptors varies widely in soft tissue sarcomas.
3. Aims of the study
This thesis aimed to evaluate the outcome of oncological treatments in 
desmoid tumors in a single-institution series. Furthermore, the goal was to 
identify novel biomarkers to predict recurrence and understand the 
underlying pathogenesis better. 
The specific objectives of this study were as follows:
I To study the outcome of radiotherapy and the patterns of recurrence after 
radiotherapy in desmoid tumors,
II To investigate the activity of cyclin-dependent kinase 4/6 inhibitor
ribociclib combined with hormonal therapy in desmoid tumor, and 
III–IV To evaluate the predictive impact of critical cell cycle regulators such 
as cyclin A, D1, Ki67, and ERβ as markers of disease recurrence and their 
possible association with other clinicopathological variables.
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4. Patients and methods
4.1. PATIENTS
Data on clinical parameters were obtained from medical records, and time of 
death was acquired from the Population Register Center. In all the studies, 
histologic slides were reviewed, and an experienced sarcoma pathologist 
confirmed the diagnosis.
4.1.1. STUDY I
Our radiotherapy study consisted of 41 eligible patients and 44 tumors treated 
with 49 courses of radiotherapy at Helsinki University Hospital between 1987 
and 2010. Due to missing imaging for response evaluation, two patients were 
evaluated only in the dose distribution analysis. Six radiotherapies in four 
patients were not included in the final analysis due to inadequate follow-up, 
imaging, or concurrent medical therapy. 
The median age at diagnosis was 45, and the majority of patients were female 
(68%, 28/41). FAP had affected 10% (4/41) of the patients. Margins were 
classified as positive in 43% (21/49) and negative in 5% (5/49), and 47% 
(23/49) of radiotherapies were sole treatments. The demographics and the 
tumor characteristics at initial presentation are listed in Table 4.
Only adult patients received radiotherapy. Photons were used in 39, electrons 
in four and both in four radiotherapy courses. Radiotherapy was carried out 
either with static fields (41) or using intensity-modulated radiotherapy 
(IMRT) technique (4). Two treatments did not include the details of the used 
radiation technique.
Table 4. Clinical variables in studies I, III, IV, and in the complete tissue microarray (TMA) series 
(modified from studies I, III, and IV).
I TMA III IV
n 41 90 76 83
Median age at diagnosis 45 (5–79) 35 (17–78) 35 (17–72) 35 (17–72)
Gender
Female 28 63 53 59
Male 13 27 23 24
Pregnancy associated (%) 0 13 (15) 11 (15) 13 (16)
FAP 4 (10) 11 (12) 9 (12) 11 (13)
Median tumor diameter, 
cm
8 (2–26) 6 (1–40) 6 (1–40) 6 (2–40)
Site
Trunk 14 (34) 57 (63) 50 (66) 54 (65)
Extremities 21 (51) 17 (19) 15 (20) 15 (18)
Head and neck 2 (5) 6 4 (5) 4 (5)
Intra-abdominal 2 (5)a 9 (10) 6 (8) 9 (11)
Multicentric 4 (10) 1 (1) 1 (1) 1 (1)
Surgery and margins
Margin negative 5 (10) 45 (50) 35 (46) 39 (47)
Margin positive 21 (43) 27 (30) 24 (32) 26 (31)
Unknown or no surgery 23 (47)b 18 (20) 17 (22) 18 (22)
Median follow-up time, 
years 
7 (0.8–17) 11 (0.1–29) 11 (0.1–29) 11 (0.1–29)
aTwo multifocal diseases included an intra-abdominal tumor.
bIn study I 44 tumors were treated with 49 radiotherapy courses of which 
radiotherapy alone was carried out in 23 treatments.
TMA = tissue microarray, FAP = familial adenomatous polyposis
4.1.2. STUDY II
Study II describes a case report of a young female with FAP and multiple 
desmoid tumors located in the abdominal wall, upper arms, chest wall, and 
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back and suprapubic regions. To prevent the development of colorectal cancer,
she underwent a prophylactic colectomy. Due to desmoid tumors, she was 
treated with eight resections, four radiotherapies, and several lines on 
systemic therapy before experimental treatment with ribociclib, letrozole, and 
goserelin. Radiotherapy was delivered in 2 Gy fractions with total doses of 50 
Gy, 60 Gy, 40 Gy, and 60 Gy. 
4.1.3. STUDIES III AND IV
Study III included 73 and study IV 83 surgically treated desmoid tumor 
patients. Patients were handled at Helsinki University Hospital between years
1987 and 2011. In both studies, females predominated by 69.7% and 71.1%, 
respectively. Table 4 summarizes demographic and baseline characteristics in 
studies III and IV. All the patients included in the survival analysis underwent 
R0 or R1 resection.
4.2. CLINICAL AND RADIOLOGICAL DATA (I, II)
The responses after radiotherapy and systemic therapy in studies I and II were 
reassessed according to RECIST 1.1. criteria. Additionally, in study II, the 
treatment with ribociclib, letrozole, and goserelin was evaluated according to 
WHO criteria. In study II, only non-irradiated tumors and growing tumors 
after previous irradiation were included. 
In study I, the recurrences were delineated in CT/MR images using treatment 
planning software (Eclipse® 11.0, Varian Medical Systems Inc., Helsinki, 
Finland). The recurrence images were then rigidly co-registered with the 
initial dose plan. Anatomical landmarks were used to achieve optimal co-
registration. The locations of treatment failures were grouped as in-target, 
marginal, and out-of-target. In-target recurrence situated ≥ 95% within the 
volume receiving ≥ 95% of the prescribed radiation dose. A marginal relapse
crossed the 95% isodose, and less than 95% of the relapse volume was located 
inside the volume receiving ≥ 95% of the radiation dose. Out-of-target failure
was outside the 95% isodose of the target volume.
4.3. IMMUNOHISTOCHEMISTRY (III, IV)
A TMA was created of paraffin-embedded formalin-fixed desmoid tumor 
tissue blocks. The pathologist defined and marked the representative tumor 
areas to the donor block, and three or more core biopsies of each block were 
punched using a 1-mm-diameter punch with a manual microarrayer 
(BeecherInstruments Inc, Silver Spring, MD, USA). Three parallel recipient 
tissue array blocks were formed from the cylindrical tissue cores. Human 
colon, stomach, and pancreas tissue specimen were implanted in the block 
corner as a reference for staining intensity and orientation.
After the tissue blocks were sectioned into 4-μm slides, they were 
deparaffinized in xylene and hydrated multiple times through graded alcohols. 
Heat-mediated antigen retrieval with Tris-EDTA buffer solution (pH9) was 
used. After that, the specimen was stained with cyclin A (Ventana, Arizona, 
USA), cyclin D1 (Ventana, Arizona, USA), Ki67 (Novocastra, Newcastle, UK),
and estrogen receptor-β (Ventana, Arizona, USA) antibodies (see Table 5 for 
antibodies and dilutions). The section was subjected to pretreatment and 
staining with the Autostainer 480 (LabVision, Fremont, CA, USA) using Dako 
REAL EnVision Detection System. Counterstaining was conducted with 
hematoxylin and 3,3-diaminobenzidine (DAB+) solution. Finally, the slides 
were mounted in mounting medium (Pertex®, Histolab, Sweden).
Table 5. Antibody characteristics in studies III and IV.
Antibody Clone Source Dilution
Anti-human Ki67 
Antigen Clone MIB-1
M7240 Novocastra
(Newcastle, UK)
1:100
Cyclin D1 SP4-R Ventana Medical Systems
(Arizona, USA)
Prediluted
Cyclin A 6E6 Novocastra
(Newcastle, UK)
1:50
Estrogen receptor-β EMR02 Ventana Medical Systems
(Arizona, USA)
1:100
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The TMA sections were scanned with Pannoramic 250 digital scanner 
(3DHistech, Budapest, Hungary). Evaluable tumor areas in each of the cores 
were contoured using Pannoramic Viewer software (3DHistech, Budapest, 
Hungary). Furthermore, the percentage of the positive nuclei was determined 
with NuclearQuant software (3DHistech, Budapest, Hungary), with each core 
individually evaluated. 
The specimen with under 100 or 300 tumor cells for ERβ and proliferation 
markers were excluded from the analysis, respectively. Regarding Ki67, cyclin 
A, and cyclin D1, the cores with over 500 detected cells were primarily selected 
for further analysis; in other cases, the uppermost staining rate was chosen. 
Cyclin A, cyclin D1, Ki67, and ERβ expressions were tiered from 10th to 90th 
percentiles to find the optimal cut-off value. To compare our results with those 
of other investigators, we tested cyclin D1 cut-offs at 5% and 10% and ERβ cut-
off at 1% (Table 7).
4.4. STATISTICAL METHODS
IBM SPSS Statistics for Windows versions 22-25 (SPSS, Chicago, IL, USA) was
used for statistical analysis. Time to recurrence and time to progression (TTP) 
were calculated from the beginning of the therapy (e.g., radiotherapy, medical 
therapy) or from the first operation with curative intent until documented 
recurrence, progression, or last follow-up date. Cox regression analysis was 
performed to analyze the connection between clinicopathological parameters, 
cyclin A, cyclin D1, Ki67, ERβ, and TTR in univariate and multivariate analysis. 
Analysis of cyclin D1 was stratified for the use of adjuvant radiotherapy. 
Kaplan-Meier model was applied to compare TTR in different groups using
the log-rank test. 
For testing associations, Pearson’s analysis was utilized for continuous data, 
and Student’s t-test was used for categorical data, as appropriate. Mixed 
general ANOVA model tested the association between cyclin D1 expression 
and Ki67 separately in ERβ-positive and -negative groups. Two-tailed p-value 
was set significant when under 0.05.
4.5. ETHICAL CONSIDERATIONS
The study obtained approval from the ethics committee of Helsinki University 
Hospital (270/13/03/00/2011 and 2449/2017) and the National Supervisory 
Authority for Welfare and Health. For study II, the patient provided informed 
consent.
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5. Results
The median follow-up time was seven years in study I and 11 years in studies 
III and IV. The clinical and pathological parameters are summarized in Table 
4.
5.1. STUDY I 
The median prescribed radiotherapy dose for both postoperative and 
radiotherapy alone was 50 Gy (ranging from 20 to 63 Gy) with a median 
fraction size of 2 Gy. After definitive radiotherapy, a complete response (CR) 
was recorded in three tumors (14%), a partial response (PR) in nine (41%), and 
stable disease (SD) in ten tumors (45%) with an objective RR of 55% (12/22). 
The median time to response was 14 months and to progression four years in 
only five tumors. None of the tumors progressed within six months from the 
start of definitive radiotherapy.
After definitive or postoperative radiotherapy, the dose was the only factor that 
was significantly associated with TTP in multivariate analysis with a p-value 
of 0.02 (HR 0.7, 95%CI 0.5–0.9). Except for radiation dose in univariate 
analysis, none of the examined factors (age, gender, FAP, tumor diameter, 
location, recurrence status, surgical margin) was significantly associated with
TTP (p=0.2-0.6). The analyses of radiotherapy dose were repeated, including 
only the first treated desmoid tumors; 2 Gy fraction equivalent doses were also 
used, where radiation dose retained the significant impact on TTP. Local 
control rate was 67% (4/7) with doses under 50 Gy, 75% (24/32) from doses 
50 to 59.9 Gy, and 100% (8/8) with doses over or equal to 60 Gy. In Figure 6,
the Kaplan-Meier curve shows local control divided into groups by total 
radiation dose into 2 Gy fractions equivalent doses.
Figure 6. Time to progression in 43 patients with desmoid tumor and treated with 47
postoperative or definitive radiotherapies. Equivalent total doses to 2 Gy fractions 
were calculated with an α/β ratio of 3 Gy.
Relapses after postoperative or definitive radiotherapy were studied in 10 
patients with 10 desmoid tumors, of which one tumor was irradiated twice. In 
the local relapse analysis, two of the recurrences were located in-target, and 
nine were marginal (Table 6). None of the relapses was situated completely 
out-of-target. Two of these patients were examined only in the local relapse 
analysis due to insufficient imaging.
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Figure 7. The contoured local recurrence volume in the diagnostic magnetic resonance 
imaging (MRI) was co-registered with the radiotherapy planning computed 
tomography (CT) image. The local failure after 50 Gy in 2 Gy fractions definitive 
radiotherapy was classified as in-target.
One radiation-induced pleomorphic undifferentiated sarcoma was observed 
nine years after desmoid tumor radiotherapy. The malignancy was situated in 
the irradiated volume. The tumor was successfully resected, and no recurrence 
was detected within six years of follow-up.
Table 6. Analysis of local recurrences after 11 definitive or postoperative radiotherapies. Adapted 
from (Santti et al. 2017)
Radiotherapy 
type
Prescription 
dose (Gy)
LR
median 
(Gy)
LR
min 
(Gy)
Location of 
LR
LR in 
relation to 
boost
1 Definitive 50 42.4 7.6 Marginal Marginal
2 Postoperative 60 58.6 4.1 Marginal Marginal
3 Postoperative 50 0.5 0.2 Marginal
4 Definitive 50 50.3 19.8 Marginal
5 Definitive 30.6 5.8 0.7 Marginal
6 Postoperative 60 3 0.7 Marginal Out-of-target
7 Postoperative 45 44.7 44 In-target In-target
8 Postoperative 50 35.6 2.6 Marginal
9 Definitive 46 37.9 0.8 Marginal
10 Definitive 50 48.7 26.4 Marginal
11 Definitive 50 49 24.6 In-target
LR = local recurrence
5.2. STUDY II
Ribociclib 600 mg was combined with monthly goserelin 3.6 mg s.c. and daily 
letrozole 2.5 mg p.o with three weeks on and one week off dosing schedule. 
After the initiation of treatment, the patient could reduce the dose of opioids 
as the pain eased. The treatment with ribociclib, letrozole, and goserelin 
stabilized the growth of multiple desmoid tumors. The sum of perpendicular 
measures decreased by 18% according to WHO criteria. Adverse events 
included grade 1 fatigue, neck pustules, vesicular hand rash, and tumor 
itching. Due to grade 3 to 4 neutropenia, ribociclib was first reduced to 400 
mg and subsequently to 200 mg. Ten months after the initiation of the 
ribociclib-based therapy, it was discontinued due to grade 4 neutropenia 
despite several dose reductions. A pleural lesion started to grow quickly and 
was irradiated with 30 Gy total dose in 10 daily fractions.
A month after the discontinuation of the therapy, deep leucopenia 0.8 109/l 
and thrombocytopenia 64 g 109/l was detected. Acute promyelocytic leukemia 
was diagnosed from a bone marrow aspirate and verified with fluorescent in 
situ hybridization. The patient was hospitalized for leukemia therapy. With all-
trans retinoic acid and arsenic trioxide therapy, morphological and molecular 
remission was achieved.
Responses and TTP for all pharmacological agents are displayed in Figure 8. 
For this patient, partial response was achieved with toremifene, and the 
disease was stabilized with the combination of goserelin and toremifene as 
well as with goserelin and letrozole.
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○ = partial response, ◊ = stable disease, ∆ = progressive disease
Figure 8. Outcome of systemic therapies in one patient in study II assessed by TTP and 
RECIST criteria 1.1. Modified from (Santti, Beule, et al. 2019)
5.3. STUDIES III AND IV
The median immunopositivity of Ki67 was 3.9%, cyclin A 1.5%, cyclin D1
15.6%, and ERβ 10.8%. Table 7 summarizes the expressions of these 
biomarkers in studies III and IV. β-catenin was expressed in all tumors, when 
positive expression was defined as detectable staining.
Table 7. Expression of estrogen receptor β and proliferation biomarkers Ki67, cyclin A, and cyclin 
D1.
n Median 
positivity % 
Cut-off % 
(≥positive)
High 
expression (%)
Ki67 ͹Ͳ ͵ǤͻȋͲǤ͵Ȃͳ͵ǤͺȌ ͷǤͻͻ ͵Ͳ
Cyclin A ͹Ͷ ͳǤͷȋͲȂͻǤͻȌ ʹǤͻͺ ͳͻ
Cyclin D1 ͹͹ ͳͷǤ͸ȋͲǤ͹ȂͻͲǤ͹Ȍ ͷ ͺʹ
ͳͲ ͸Ͷ
Estrogen receptor β ͺ͵ ͳͲǤͺȋͲȂ͹ͶȌ ͳ ͺʹ
ʹͺǤͻ ʹͻ
In Cox multivariate analysis, high expression of cyclin A (HR 1.9, 95%CI = 1.1–
3.2, p = 0.02), positive surgical margin (HR 6.0, 95%CI = 1.6–22.5, p = 0.008), 
and extremity location (HR 5.3, 95%CI = 1.7–16.8, p = 0.005) were associated 
with faster recurrence. When cyclin A expression was divided into percentiles, 
cut-off value 2.98% at 80th decile was associated with worse TTR with HR of 
3.5 (95% CI = 1.4–6.6, p = 0.006). 
High Ki67 or cyclin D1 immunopositivity did not significantly predict for 
recurrence either in univariate analysis or when divided into two groups. Ki67 
showed the highest HR of 2.3 with the cut-off value of 5.99% at 70% percentile 
(p = 0.07) approaching the limit of significance. In univariate analysis, the 
high expression of ERβ appeared to be linked with short TTR with a hazard 
ratio of 1.02 (95% CI = 1.0–1.04, p = 0.06). The association was significant 
(HR 2.6, 95% CI 1,2–6.0, p = 0.02) when ERβ expression was divided into 
groups at 70% percentile with 28.9% cut-off value.
55
Figure 9. Scatter diagram demonstrates a significant positive linear relationship between
estrogen receptor β and cyclin D1 immunoexpression rates (rp=0.34, p=0.004).
Cyclin D1, cyclin A and Ki67 immunoexpression levels showed significant 
positive correlations with one another (p≤0.001-0.004), with correspondingly
increasing rates. A positive correlation was observed between proliferation 
markers and ERβ immunoactivity (p=0.001-0.004), Figure 9 illustrates the
connection between ERβ and cyclin D1 rates. Correlations between all 
analyzed biomarkers and clinicopathological parameters are listed in Table 8.
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6. Discussion
6.1. RADIOTHERAPY IS EFFECTIVE IN DESMOID 
TUMORS (I)
Studies comparing outcome after radiotherapy alone and surgery combined 
with adjuvant radiotherapy have yielded similar results with no statistically 
meaningful difference in local control between the groups (Nuyttens et al. 
2000; Yao et al. 2014). This finding is in accordance with our results as surgery 
before radiotherapy had no significant impact on TTP. In case achieving 
adequate surgical marginals is not possible or would cause significant 
morbidity, radiotherapy alone should be considered. However, long-term 
radiation-related toxicity should be noted, and systematic therapy should be 
considered as another option especially in young patients. 
In our series, the objective RR was 55% after radiotherapy alone. The
European Organisation for Research and Treatment of Cancer (EORTC)
conducted a prospective phase II study including 44 patients with an 
inoperable primary, recurrent, or incompletely operated desmoid tumor and 
treated with radiotherapy as the sole treatment (Keus et al. 2013). Echoing our 
results, the EORTC study showed that the objective RR was 50%.
Furthermore, the local control rate was 81.5% at three years using moderate 
dose radiation of 56 Gy in 28 fractions (Keus et al. 2013). In our study, the five-
year local control rate after definitive or postoperative radiotherapy was
comparable, 77%, with a median radiation dose of 50 Gy. The reported long-
term local control after radiotherapy alone has varied in different series from 
70% to 93% (Spear et al. 1998; Guadagnolo, Zagars, and Ballo 2008; Nuyttens 
et al. 2000). This evidence illustrates that radiotherapy is a powerful treatment 
modality in desmoid tumors with a favorable long-term outcome.
The optimal radiation dose has been a subject of controversy in desmoid tumor
management. Our study demonstrated a significant dose-response
relationship in multivariate analysis in patients treated with radiotherapy. 
Previously dose-response has been reported in studies with superior local 
control, using doses over 45 to 54 Gy (Nuyttens et al. 2000; Baumert et al. 
2007; Ballo, Zagars, and Pollack 1998; Choi et al. 2018; Ergen et al. 2016), 
while other authors barely succeeded in detecting a dose-response 
relationship (Zlotecki et al. 2002; Gluck et al. 2011). However, recurrences can 
occur even with doses ≥ 60 Gy, and radiation-related morbidity exceeds with 
higher doses (Ballo et al. 1999; Spear et al. 1998). A large portion of desmoid
patient population has decades of life left. Therefore, for radiotherapy alone,
56 Gy and postoperative radiotherapy 50 Gy in once-daily fractions of 2 Gy
have been recommended (Kasper, Baumgarten, et al. 2017). In our analysis,
no other factor (age, tumor size or location, recurrence status, surgical margin)
alongside radiation dose influenced progression-free time, which may be due 
to the small patient cohort and selection of patients treated only with 
radiotherapy.
We investigated radiological failure patterns following radiotherapy of 
desmoid tumors. In literature, the majority of local recurrences have emerged 
in-field, contrasting our analysis with 82% (9/11) of recurrences classified as 
marginal and only 18% (2/11) as in-target (Nuyttens et al. 2000; Guadagnolo, 
Zagars, and Ballo 2008). One reason for the difference might be diverse or
absence of definitions of local failures. Notably, in our study, local failure was 
classified marginal if only a portion of the relapse received a total radiation 
dose. However, CT/MR images of recurrences were not implemented in the 
treatment position and while using immobilization. These facts and the use of 
rigid image coregistration might have led to small inaccuracies in the 
determination of patterns of failure. In line with our results, a study using
dose-distribution analysis reported 61% (11/18) of relapses situated at the 
margin of target volume or in areas receiving less than 50 Gy (Baumert et al. 
2007). In our analysis, both in-target recurrences received suboptimal median 
doses of 44.7 Gy (postoperative radiotherapy) and 49 Gy (radiotherapy alone). 
The characteristic infiltrative growth of desmoid tumors may explain the high 
occurrence of marginal recurrences. Our findings emphasize the significance 
of adequate radiation dose for the target volume, precise target delineation,
and sufficient margins. We found no out-of-target recurrences, which is in 
concordance with literature (Guadagnolo, Zagars, and Ballo 2008). Of note, 
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most studies analyzing recurrences were retrospective and included an 
extensive period. During the last decades, the generalized use of MRI and 
modern radiation techniques (e.g., IMRT) may change the patterns of local 
failures after irradiation.
6.2. RIBOCICLIB MAY HAVE ACTIVITY IN DESMOID 
TUMORS (II)
In hormone-sensitive breast cancer cdk 4/6 inhibitors palpociclib, 
abemaciclib and ribociclib have shown eminent efficacy. The median PFS 
combined with ribociclib and letrozole was 25 months in postmenopausal 
women with ER-positive HER2 negative advanced or metastatic breast cancer 
(HR 0.57). With letrozole alone, the median PFS was 16 months in the phase 
III trial (Spazzapan et al. 2017). Furthermore, in the management of
metastatic or locally advanced soft tissue sarcoma palbociclib alone and 
ribociclib combined with doxorubicin are being investigated in ongoing phase 
II studies (NCT03242382 and NCT03009201). In this study, treatment with 
ribociclib, goserelin, and letrozole relieved pain and stabilized multiple 
desmoid tumors for ten months. Tumor size was reduced by 18% according to 
WHO criteria. Like estrogen-receptor-positive breast cancers, desmoid 
tumors are hormone-sensitive: Endocrine treatments have yielded 51% RR
with a 9-month median length of therapy (Bocale et al. 2011). Both in breast 
cancer and desmoid tumors, high cyclin D1 expression has been detected. In 
desmoid tumors, excessive β-catenin is involved in the regulation of cyclin D1 
gene CCND1 transcription, and in breast cancer, estrogen receptors target 
CCND1, leading to cyclin D1 overexpression (Saito et al. 2001). In breast 
cancer, hormonal therapy and cdk 4/6 inhibitors have shown synergistic effect
by cotargeting the interacting signaling pathways (Abraham et al. 2018). Our 
study suggests an activity for ribociclib combined with hormonal therapy in 
desmoid tumors, although findings of an individual case report cannot be 
generalized. Further research is required and if further case reports or series 
affirm the favourable effect of ribociclib in desmoid tumor patients a 
controlled trial should be conducted to validate the results.
RECIST 1.1. criteria have been the standard method for response evaluation in 
desmoid tumors. However, unidimensional measurements may not capture 
the response optimally as desmoid tumors show irregular and infiltrative 
growth. To optimate response evaluation in our study, we measured response 
using both WHO and RECIST criteria. Different response endpoints were also 
tested in the follow-up study of γ-secretase inhibitor PF-03084014, including 
RECIST and WHO criteria, CT density, and MRI enhancement ratio 
(Villalobos et al. 2018). The mean time to response was similar in comparison 
with RECIST and WHO criteria; however, an early decrease in MRI 
enhancement ratio correlated with a subsequent response with RECIST and 
WHO. Furthermore, automated volumetric tumor evaluation via CT or MRI 
has been suggested (Kummar et al. 2017). 
The patient developed acute promyelocytic leukemia, possibly secondary to a 
previous treatment. The effect of cdk 4/6 inhibitors on hematopoiesis is
reversible; therefore, in agreement with the literature, we believe it is unlikely 
that ribociclib had induced the secondary malignancy (Kassem et al. 2018). 
The patient was previously irradiated four times at a relatively young age and 
coped with three courses of doxorubicin, both of which are known to be 
associated with therapy-related acute promyelocytic leukemia. Radiotherapy
may be considered as the most likely contributing factor. Radiation is generally 
used with careful consideration in young desmoid patients due to occasional
indolent biology of the disease. However, for our patient, radiotherapy could 
not be avoided due to inoperable, enlarging, and symptomatic tumors. The 
patient benefited from the radiations she received.
6.3. IMMUNOEXPRESSION OF ESTROGEN RECEPTOR Β
AND PROLIFERATION BIOMARKERS IN DESMOID 
TUMORS (III AND IV)
Consistent with desmoid tumors frequently indolent clinical course, in this
study, the expression level of different cell cycle markers was generally low. 
The mean immunopositivity rate for Ki67 was 4.7%, which echo earlier 
publications with mean Ki67 expression rates from undetectable to 8.7%
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(Jilong et al. 2007; Stalinska et al. 2009; Dubova et al. 2012). Likewise, cyclin 
D1 and A positivities were low with median rates of 15.6% and 1.5%, 
respectively. Cyclin A has not been investigated previously in desmoid tumors
whereas cyclin D1 protein with a 5% cut-off has been present in up to 71% of 
desmoid tumors (Saito et al. 2001; Jilong et al. 2007). With a similar cut-off,
a higher proportion of tumors, 82%, showed positive cyclin D1 expression in 
our study, with the percentage of positive tumor cells ranging widely from 
0.7% to 90.7%. The extensive cyclin D1 expression could be explained by its
relationship with the β-catenin pathway in desmoid tumors. The vast majority 
of desmoid tumors exhibit active Wnt/β-catenin signaling, which induces the 
transcription of cyclin D1 gene CCND1. 
In desmoid tumors, the expression of ERβ has appeared diverse with positive 
expression from 7% to 100% with cut-offs from detectable to 10% (Ishizuka et 
al. 2006; Deyrup, Tretiakova, and Montag 2006). In this report with a 1% cut-
off, ERβ overexpression was detected in 82% of desmoid tumors with 10.8% 
median percentage of positive cells. Validating our results, the more recent 
publications reported positive ERβ expression from 72% to 100% of tumors
(Mignemi et al. 2012; Santos et al. 2010; Colombo et al. 2012). The variance in
results may be due to multiple cut-points used, non-standardized 
immunohistochemical methods, scoring, and differences with patient 
populations. The other primary estrogen receptor α expression has remained 
negative in desmoid tumors (Santos et al. 2010; Leithner et al. 2005).
Therefore, desmoid tumor hormonal sensitivity could be mediated via ERβ.
In desmoid-type fibromatosis large tumor diameter, young age, extremity 
location and in some studies positive surgical margin have predicted faster 
recurrence after operative treatment (Crago et al. 2013; Janssen et al. 2017; 
Yao et al. 2014). In study III positive surgical margin (HR 6.0, p=0.008) and 
extremity location (HR 5.3, p=0.005) were associated with poorer outcome
when adjusted for confounding factors. These results contrast with study I, 
where either surgical margin or tumor location predicted for recurrence. The 
explanation for the discrepancy may be the smaller number of patients in 
study I and the differing patient cohorts because the more complicated 
patients were assigned for radiotherapy. 
High cyclin A expression predicted faster recurrence after resection in 
multivariate analysis (p = 0.02, HR 0.7) whereas Ki67 and cyclin D1 had no
impact on TTP in desmoid tumors. In an explorative analysis, Ki67 showed a 
trend inclining toward the prediction of the worse outcome, although it did not 
reach statistical significance. There is an ample body of research on the 
prognostic significance of Ki67 in various malignancies. However, only in one
desmoid tumors study, Ki67 showed positive predictive value for TTR in 
univariate analysis (Brueckl et al. 2001). In agreement with our report, other
desmoid tumor studies failed to show an association between Ki67 and TTP 
(Machado et al. 2017; Mueller et al. 2016). In our study, proliferation markers 
cyclin A, cyclin D1, and Ki67 correlated with each other. The reason why cyclin 
A was the strongest predictor for recurrence could be related to its core role in 
the cell cycle. During S-phase, cyclin A/cdk1 complex triggers DNA replication.
Cyclin A has not been extensively investigated; however, cyclin A 
overexpression has been linked to a poor outcome in breast cancer, soft tissue 
sarcomas, and laryngeal carcinoma, for example (Saarilahti et al. 2003; 
Huuhtanen et al. 1999; Ahlin et al. 2009).
In our work, the positive relationship found between proliferation markers 
Ki67, cyclin D1, and cyclin A varied from lesser degree to strong. The reason 
for the variable correlation may be related to other factors influencing the cell 
cycle regulation. ERβ expression correlated positively with cell cycle markers 
Ki67, cyclin D1, and cyclin A. When divided into two groups, very high 
expression of ERβ predicted unfavourable clinical outcome in operated 
desmoid tumors, as did cyclin A. A series of 12o soft tissue sarcoma patients 
found no association between expression of ERα or β and proliferation 
measured by Ki67 (Li, Hisaoka, and Hashimoto 2003). These findings cohere 
with the absence of hormonal responsiveness in extrauterine soft tissue 
sarcomas and the known hormonal dependency in desmoid tumors. The exact 
biological role of ERβ in different tissues is not well understood. In breast 
cancer, ERβ mediates antiproliferative activity, especially in the absence or 
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low expression of ERα, whereas some studies have suggested ERβ a role in 
myofibroblastic differentiation in stromal breast cells (Tan et al. 2016; Sapino 
et al. 2006). Our results suggest that in desmoid tumors, ERβ signaling may 
be connected with both proliferation and poor outcome. 
6.4. LIMITATIONS AND STRENGTHS
This study comprised patients treated at Helsinki University Hospital. This 
selection of patients may cause referral bias because the more challenging
patients are usually admitted to a tertiary center. Availability of a
multidisciplinary sarcoma team and the consistent use of treatment guidelines 
are positive aspects of this single-institution study. Diagnosis of this rare 
disease entity can be demanding, and in this study for all patients, the 
diagnoses were reviewed and verified by an experienced sarcoma pathologist.
The retrospective study design in studies I, III, and IV may have caused
selection bias. This bias could favor surgery combined with adjuvant 
radiotherapy because larger tumors situated adjacent to vulnerable structures 
are more often addressed to radiotherapy alone. Additionally, the long period 
may have affected the outcome of the studies. Radiotherapy and surgical
techniques have evolved during the past decades, and for all the patients, the 
exact surgical margins or the tumor diameters could not be verified. The 
evaluation of treatment-related toxicity was inaccurate, and mild side effects 
were seldom recorded initially. However, the extended follow-up was the 
strength of the study.
The TMA-based technique allows evaluation of large tumor materials 
efficiently saving time, reagents, and tumoral tissue. Compared with full tissue 
sections, using TMA may cause inaccuracy due to intratumoral heterogeneity.
However, desmoid tumors consist of relatively homogenous tissue. TMA has 
been validated in fibroblastic tumors with an excellent 96% concordance with 
triplicate cores when Ki67 was examined in two categories (Hoos et al. 2001). 
We used at least three cores per specimen in three parallel TMA slides to 
ensure the accuracy of the results. Simultaneous processing of several tumor 
specimens in one array may decrease the variability related to 
immunohistochemical staining. A number of factors can influence the 
outcome in immunohistochemistry: fixation, sectioning, slide storage time, 
inadequate deparaffination, antigen retrieval technique, selection of antibody 
clones and reagents, counterstaining and interpretation procedure. We used 
digital image analysis for quantitative assessment of nuclear biomarker 
expression. The analysis was not fully automated, allowing monitoring and 
adjustments in each sample if needed. Visual screening may be challenging,
especially when assessing low proliferation (Kwon et al. 2019). In breast 
cancer, digital analysis of Ki67 has shown very high inter-operator 
reproducibility (Acs et al. 2019). Due to increased efficacy, accuracy, and 
technological advances, the use of digital pathology is emerging both in 
research and clinic in the near future.
The patient cohort was relatively small, as was the number of events, which 
reduced the statistical power in multivariate analysis. However, taking into 
account the extremely low incidence of desmoid tumors, our patient cohort 
size was above average and could be considered a valuable contribution in this
field. 
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7. Conclusions
Our results indicate that radiotherapy is an effective treatment in desmoid 
tumors. Indeed, surgery before radiotherapy did not improve the outcome. We 
also found a positive dose-response relationship for patients treated with 
radiotherapy. Most local failures after radiotherapy seem to be due to
inadequate coverage of the target volume and extremely low dose level. In 
combination with endocrine treatment, our case presentation shows that 
ribociclib seems to have clinical activity in desmoid tumors.
High cyclin A expression independently predicts faster recurrence in operated 
desmoid tumors. More precise risk stratification might aid decision-making 
about additional therapy after surgery. Furthermore, our study illuminates the 
connection between ERβ signaling and proliferation in desmoid tumors.
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